Xcout Intel
Vaxcyte, Inc. competitors & alternatives
The 12 closest competitors and alternatives to Vaxcyte, Inc. among biotechnology companies — ranked by similarity to what Vaxcyte, Inc. actually does, not by market-cap band.
Subscribe to see Vaxcyte, Inc.’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
About Vaxcyte, Inc.
Vaxcyte, Inc. is a biotechnology firm in the clinical development stage, dedicated to creating innovative protein-based vaccines. Its primary objective is to either prevent or manage bacterial infectious diseases. The company's leading vaccine candidate is VAX-24, an experimental 24-valent pneumococcal conjugate vaccine currently undergoing Phase 1/2 clinical trials, intended to address invasive pneumococcal disease and pneumonia. Beyond its flagship candidate, Vaxcyte is also advancing several other vaccine programs: VAX-XP, designed to offer protection against emergent bacterial strains and counter antimicrobial resistance; VAX-A1, a conjugate vaccine formulation aimed at Group A Streptococcus; and VAX-PG, a novel protein vaccine specifically developed to target the key pathogen responsible for periodontitis. The organization, which was initially established as SutroVax, Inc., officially rebranded as Vaxcyte, Inc. in May 2020. Founded in 2013, its corporate headquarters are situated in San Carlos, California.
Vaxcyte, Inc. at a glance
Vaxcyte, Inc. is a biotechnology company headquartered in San Carlos, United States. It is publicly listed (PCVX) with a market capitalisation of $10.3B. Xcout tracks 27 named people at Vaxcyte, Inc., including Andrew L. Guggenhime (President & Chief Financial Officer). Xcout recorded 98 job postings from Vaxcyte, Inc. in the last 90 days.
Vaxcyte, Inc. leadership
- Andrew L. GuggenhimePresident & Chief Financial Officer
- Andrew GuggenhimePresident and Chief Financial Officer
- James WassilExecutive Vice President & Chief Operating Officer
- Harp DhaliwalChief Technical Operations Officer
- Chris GriffithChief Business and Strategy Officer
- David McAvoyChief Legal Officer, Chief Compliance Officer & Corporate Secretary
21 more named people on record for Vaxcyte, Inc., with roles, board committees and tenure — see the full roster →
Hiring at Vaxcyte, Inc.
Xcout recorded 98 job postings from Vaxcyte, Inc. in the last 90 days, from a hiring record Xcout has kept since June 2026.
The weekly hiring trend, the roles and locations behind it — see Vaxcyte, Inc.'s hiring signals →
Top 12 Vaxcyte, Inc. competitors
Ranked by semantic similarity — how close each company is to Vaxcyte, Inc. by what it does, using Xcout's live company graph. Click any company for its full profile, or its competitor set.
Similar biotechnology company
Ventyx Biosciences, Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for inflammatory and autoimmune diseases. Headquartered in California, the company advances a robust clinical pipeline and operates as a publicly traded enterprise.
Similar biotechnology company
Centivax is a privately held, clinical-stage biotechnology company headquartered in South San Francisco, California. The company focuses on accelerating the transition to a post-pathogen world by developing broad-spectrum vaccines, COVID-19 therapeutics, and antivenom antibodies.
Similar biotechnology company
Alopexx, Inc. is a U.S. biotechnology company developing broad-spectrum anti-infective vaccines and antibody-based therapies. Its programs target PNAG, a surface polysaccharide found on many bacterial and fungal pathogens, for potential treatment or prevention of serious infections.
Biotech
Vaccinex, Inc. is a biotechnology firm operating in the clinical stage, dedicated to identifying and developing specialized biological therapies. Its core mission is to address serious medical conditions and diseases that currently lack adequate treatment options. The company's therapeutic endeavors encompass a broad spectrum of illnesses, including various forms of cancer, neurodegenerative disorders, and autoimmune diseases. At the forefront of its pipeline is pepinemab, a humanized monoclonal antibody. This leading candidate has either concluded or is scheduled for Phase 1b/2 clinical investigations, exploring its efficacy against non-small cell lung cancer (NSCLC), head and neck squamous cell carcinoma (HNSCC), Huntington's disease, Alzheimer's disease, osteosarcoma, and melanoma. Furthermore, Vaccinex is progressing with VX5, a human antibody targeting CXCL13, which is presently in preclinical assessment for potential application in multiple sclerosis (MS) and other autoimmune conditions. The company was established in 2001 and has its principal operations located in Rochester, New York.
Similar biotechnology company
Vaxdyn is a Seville-based biotechnology spin-off founded in 2011 that develops safe and effective multi-pathogen vaccines to prevent dangerous bacterial infections.
Similar biotechnology company
Vaxxas is a clinical-stage biotechnology company headquartered in Brisbane, Australia. It is commercializing a novel vaccination technology designed to enhance the performance of existing and next-generation vaccines, and opened a biomedical manufacturing facility in Brisbane in June 2023.
Similar biotechnology company
Icosavax, Inc. is a Seattle, Washington-based clinical-stage biopharmaceutical company specializing in developing novel vaccines utilizing virus-like particle technology.
Biotech
BioVaxys Technology Corp. (BVAXF) is a clinical-stage biotechnology company primarily engaged in the development of innovative vaccine platforms targeting both antiviral diseases and various forms of cancer. Its product pipeline features several key candidates, including two SARS-CoV-2 vaccines: BVX-0320, a monovalent version, and BVX-0121, a multivalent option. In the oncology space, BioVaxys is advancing BVX-0918A, a haptenized tumor cell vaccine designed for ovarian cancer, and BVX-0918C, aimed at cervical cancer. The company also has programs addressing Human Papillomavirus (HPV), such as Papilocare for HPV-dependent cervical lesions and the BVX-0204 HPV viral vaccine. Furthermore, BioVaxys offers CoviDTH, an immunodiagnostic tool developed to detect immune system responses in individuals previously exposed to SARS-CoV-2. To support its development initiatives, BioVaxys has established several strategic collaborations. It holds a bioproduction agreement with WuXi Biologics Limited for the manufacturing of SARS-CoV-2 s-proteins, crucial components for BVX-0320 and CoviDTH. The company also has a research collaboration for BVX-0320 with The Ohio State University, Wexner School of Medicine. Additionally, Bioanalytical Systems, Inc. is conducting preclinical toxicology studies for BioVaxys' CoviDTH immunodiagnostic under a separate agreement. The company's operations are headquartered in Vancouver, Canada.
Biotech
Sutro Biopharma, Inc. is a clinical-stage biotechnology company focused on the discovery, development, and manufacturing of innovative therapeutic products. Its primary objective is to create protein-based treatments for challenging conditions like cancer and autoimmune disorders. The company achieves this through its proprietary XpressCF+ platform, a unique technology that integrates cell-free protein synthesis with precise, site-specific drug conjugation. Currently, Sutro's pipeline features two lead antibody-drug conjugate (ADC) candidates, both undergoing Phase 1 clinical evaluation. STRO-001 targets the CD74 protein, designed for individuals with multiple myeloma and non-Hodgkin lymphoma. The second candidate, STRO-002, is engineered to bind to folate receptor-alpha, intended for the treatment of ovarian and endometrial cancers. Strategic alliances are also a key part of its strategy, including collaborations and licensing agreements. A partnership with Merck aims to advance research programs involving cytokine derivatives for both oncological and autoimmune applications. Additionally, an agreement with Celgene Corporation focuses on identifying and developing bispecific antibodies and/or ADCs specifically within the immuno-oncology domain. Founded in 2003, the company initially operated under the name Fundamental Applied Biology, Inc. Its corporate headquarters are located in South San Francisco, California.
Life Sciences
Omniose is an early-stage biotechnology and life sciences company headquartered in Saint Louis, Missouri. The firm develops polysaccharide conjugate vaccines against serious bacterial threats using its proprietary technology.
Similar biotechnology company
Affinivax, Inc. is a clinical-stage biopharmaceutical company based in Cambridge, Massachusetts, that pioneered a novel class of multiplex vaccine technologies.
Biotech
Barinthus Biotherapeutics plc, a clinical-stage biopharmaceutical firm, is dedicated to pioneering innovative T-cell immunotherapies. These cutting-edge treatments are engineered to harness the body's own immune system to effectively combat chronic infectious diseases, autoimmune disorders, and various cancers. The company is actively progressing a robust portfolio of experimental medicines spanning diverse medical fields. Prominent among these is VTP-300, an immunotherapeutic candidate striving to achieve a functional cure for chronic Hepatitis B virus (HBV) infection. Also in development is VTP-200, a non-surgical therapeutic option aimed at persistent high-risk human papillomavirus (HPV). For autoimmune conditions, VTP-1000 is an autoimmune candidate leveraging the proprietary SNAP-TI platform to treat celiac disease. Additionally, VTP-850 is a next-generation immunotherapeutic designed to address recurrent prostate cancer. Furthermore, the preclinical candidate VTP-1100 utilizes the SNAP-CI platform in its development as a potential treatment for HPV-related cancers. Originally established in 2016 under the name Vaccitech plc, the company rebranded to Barinthus Biotherapeutics plc in November 2023. Its main office is located in Harwell, United Kingdom.
Analyze another company
Search any company we track to see its competitive set.
Or describe a company
Paste a short paragraph describing a company or product — we'll find the most similar companies we track, scored 1–100.
See the full profile of Vaxcyte, Inc. and its market
Funding, investors, tech stack, hiring signals, leadership and corporate events — for Vaxcyte, Inc.and every competitor above — in one live dashboard.
Subscribe to Xcout Intel →